Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 23Active not recruiting 9Not yet recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Breast Neoplasms 52Neoplasms 36Colorectal Neoplasms 33Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 30Pancreatic Neoplasms 21Multiple Myeloma 16Recurrence 14Ovarian Neoplasms 14Uterine Cervical Neoplasms 12Leukemia, Myeloid, Acute 11Carcinoma, Hepatocellular 11Neoplasm Metastasis 10Head and Neck Neoplasms 10Brain Neoplasms 10Melanoma 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 8Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Glioblastoma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Glioma 6Esophageal Neoplasms 6Colonic Neoplasms 6

Interventions

liposomal doxorubicin 1irinotecan sucrosofate 1Topotecan 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Fallopian Tube Neoplasms × 30 days × Clear all
NCT07604766 2026-06-02

RAINFOL-02

Genmab

Phase 3 Not yet recruiting
82 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07495124 2026-05-26

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

University of Washington

Phase 2 Not yet recruiting
26 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡